Bio Pharma Dive
JANUARY 16, 2025
Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors and executives interviewed by BioPharma Dive at the J.P. Morgan Healthcare Conference.
XTalks
JANUARY 16, 2025
BlueRock Therapeutics, a subsidiary of Bayer AG, is making waves in the treatment of Parkinsons disease by advancing its investigational cell therapy, bemdaneprocel, to a Phase III clinical trial. Called exPDite-2, the registrational trial meaning a trial designed to gather the necessary data for potential regulatory approval is slated to begin in the first half of 2025.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JANUARY 16, 2025
Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.
Rethinking Clinical Trials
JANUARY 16, 2025
Speakers Dana Dailey PT, PhD Assistant Research Scientist Physical Therapy and Rehabilitation Science University of Iowa Associate Professor, Physical Therapy Department St. Ambrose University Heather Schacht Reisinger, PhD Director, Implementation Science Center Associate Director for Engagement, Integration, and Implementation Institute for Clinical and Translational Science Professor, Division of General Internal Medicine at the University of Iowa Slides Keywords Commun
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
JANUARY 16, 2025
AbbVie's CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained what it got wrong forecasting GLP-1 drug demand.
XTalks
JANUARY 16, 2025
Qiagen received FDA clearance for its new QIAstat-Dx mini gastrointestinal panel last week. According to Qiagen, the test is the first in a series of QIAstat-Dx gastrointestinal (GI) panel tests for clinical use. The new QIAstat-Dx Gastrointestinal Panel 2 mini B&V (bacterial and viral) is designed for the rapid outpatient diagnosis of gastrointestinal conditions.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Antidote
JANUARY 16, 2025
When preparing for flu season, those with asthma may have concerns about how the virus can affect their respiratory health and breathing. While asthma is a manageable condition, it does require extra care when dealing with seasonal illnesses like the flu. In this blog, we'll explore how asthma and the flu interact, provide tips for managing both, and offer resources to help you stay informed and prepared.
Pharmaceutical Technology
JANUARY 16, 2025
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
Bio Pharma Dive
JANUARY 16, 2025
The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success in diabetes and obesity.
Pharmaceutical Technology
JANUARY 16, 2025
At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling effect on clients.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
XTalks
JANUARY 16, 2025
Sling Therapeutics has positive topline results from its Phase IIb/III LIDS clinical trial evaluating its oral small-molecule therapy linsitinib for the treatment of thyroid eye disease (TED). The trial met its primary endpoint of proptosis (protrusion of the eyeball from the orbit) reduction with statistical significance at the 150 mg BID (twice a day) dose.
Pharmaceutical Technology
JANUARY 16, 2025
The radiopharmaceutical developer expanded its reach, acquiring R&D, isotope production, manufacturing, and distribution.
Drug Patent Watch
JANUARY 16, 2025
The Rise of AI in Patent Intelligence AI has been making strides in various industries, and the patent sector is no exception. The integration of AI into patent intelligence has been a game-changer, offering unprecedented levels of efficiency, accuracy, and depth in analysis. Generative AI and Large Language Models (LLMs) Generative AI, particularly Large Language Models (LLMs), has become a cornerstone in the evolution of patent intelligence.
Pharmaceutical Technology
JANUARY 16, 2025
Santhera Pharmaceuticals has started launch preparations for its DMD drug Agamree (vamorolone) in the UK, after a recommendation from NICE.
Pharma Times
JANUARY 16, 2025
New partnership to advance precision medicine in lung cancer diagnosis
Pharmaceutical Technology
JANUARY 16, 2025
The new pan-European group of 73 regulators, companies and trial sites is backed by 66.8m in funding with a six-year goal.
Pharma Times
JANUARY 16, 2025
Partnership aims to advance Alzheimer's research with innovative tools
Pharmaceutical Technology
JANUARY 16, 2025
Lyndra Therapeutics and Thermo Fisher Scientific have entered a strategic partnership for Lyndra's long-acting oral therapies.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
JANUARY 16, 2025
AI start-up Bioptimus takes its funding above $76m as it prepares for the launch of a universal foundation model for pathology later this year.
Pharmaceutical Technology
JANUARY 16, 2025
Be Biopharma has secured $92m in a Series C financing round to advance its clinical programmes for haemophilia B and hypophosphatasia.
pharmaphorum
JANUARY 16, 2025
Eli Lilly picks up a second FDA approval for IL-23 inhibitor Omvoh in Crohn's disease, but will it kickstart sales growth
Pharmaceutical Technology
JANUARY 16, 2025
Treating the growing problem of childhood obesity calls for exploring new approaches and treatments through well-designed clinical trials.
pharmaphorum
JANUARY 16, 2025
The FDA has banned the use of a red dye used in oral medicines, foods, and dietary supplements, more than 30 years after it was linked to cancer.
Pharmaceutical Technology
JANUARY 16, 2025
GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.
pharmaphorum
JANUARY 16, 2025
Santhera will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks after getting the green light for NHS coverage
Pharmaceutical Technology
JANUARY 16, 2025
Meridian Medical Technologies has won a new contract worth up to $129m from the US for the supply of its DuoDote nerve agent antidote autoinjectors to the SNS.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Outsourcing Pharma
JANUARY 16, 2025
Driving Innovation in Clinical Trials: Patient Perspectives and Multidimensional Assessments
pharmaphorum
JANUARY 16, 2025
Across every corner of the industry, from research and development to patient engagement, AI, and most recently generative AI (GenAI), is driving profound change.
Outsourcing Pharma
JANUARY 16, 2025
Explore WCG's cutting-edge AI and tech solutions, including ClinSphere Total Enrollment, transforming clinical trials at SCOPE 2025.
pharmaphorum
JANUARY 16, 2025
Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC).
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
361 
Let's personalize your content